Shira Koss, MD
Otolaryngology · New York, NYNPI 1356617534
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $5,760 of the $6,832 with a category attached, or 84.3%. Intersect ENT, Inc. accounts for 84.3% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2019 at $5,783 and has fallen 96.8% since, to $188 in 2025.
Across 46 payments — averaging $148.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intersect ENT, Inc.$6K
- GSK$260
- Optinose US, Inc.$226
- Regeneron Healthcare Solutions, Inc.$183
- Sanofi$170
- Acclarent, Inc$52
- plus $181 from 4 others
What the payments were for
- Consulting fees$5,76084%
- Food & beverage$1,07216%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intersect ENT, Inc. | 2 | $5,760 |
| GSK | 13 | $260 |
| Optinose US, Inc. | 10 | $226 |
| Regeneron Healthcare Solutions, Inc. | 8 | $183 |
| Sanofi | 3 | $170 |
| Acclarent, Inc | 2 | $52 |
| Stryker | 1 | $48 |
| Phadia US Inc. | 3 | $48 |
| Merck | 2 | $46 |
| Medtronic | 2 | $38 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DUPIXENT$125
How this compares
$6,832 in reported general payments places this provider in the 85th percentile of 701 otolaryngology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ipratropium Bromide | 264 | $5,953 |
| Fluticasone Propionate | 392 | $4,076 |
| Azelastine Hcl | 172 | $3,130 |
| Ofloxacin | 99 | $2,921 |
| Doxycycline Monohydrate | 72 | $1,076 |
| Fluocinolone Acetonide Oil | 28 | $1,048 |
| Methylprednisolone | 155 | $887 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 87 | $844 |
| Famotidine | 89 | $360 |
| Omeprazole | 75 | $350 |
| Prednisone | 27 | $157 |
| Mupirocin | 13 | $101 |
| Chlorhexidine Gluconate | 15 | $52 |
| Amoxicillin | 12 | $45 |
Paid to pharmacies, not to this prescriber.
Other otolaryngology in New York
- Roheen RaithathaNew York$830K
- Dennis KrausNew York$159K
- Anthony DelsignoreNew York$89K
- Satish GovindarajNew York$39K
- Lawrence LustigNew York$33K
- Justin GolubNew York$30K
- Brett MilesNew York$30K
- David HiltzikNew York$25K
- Milan AminNew York$23K
- Ashutosh KackerNew York$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.